Regardless of BAP1 mutation or other mutations in UM cell lines, the observation that the EC50 of AU-011 treatment is in the picomolar range indicates that most UM cells are sensitive to AU-011 treatment, as previously shown by Kines et al.9This notion may be attributed to the lack of resistance mechanisms against the targeted necrosis-induced cell death,the exposure of tumor neoantigens and the unique characteristics of AU-011 that make it a treatment that is potentially genetic mutation agnostic. The gene discussed is BAP1; the disease is neoplasm.